Customize your JAMA Network experience by selecting one or more topics from the list below.
Inflammatory processes are implicated in the development and progression of cancer. However, it is not clear whether systemic markers of inflammation predict cancer. In a population-based cohort of older individuals free of cancer at the baseline examination, white blood cell count in the highest quartile compared with the lowest quartile was found to be associated with a relative risk of 1.7 for all cancer mortality (P<.05), independent of several important confounders. These results provide epidemiological evidence of an association between circulating white blood cell count, a widely available marker of inflammation, and subsequent cancer mortality.
There is growing evidence that outpatient treatment with low-molecular-weight heparin is feasible and safe in many patients with nonmassive pulmonary embolism (PE). However, outpatient treatment for this disease is not well accepted because no explicit criteria exist to identify patients with PE who are at low risk of adverse outcomes. Using retrospective data from 15 752 patients with PE from 189 hospitals in the United States, Switzerland, and France, Aujesky et al derived and internally and externally validated a simple and objective clinical model that accurately identifies patients with PE who are at low risk for 30-day mortality and severe nonfatal medical outcomes.
In This Issue of Archives of Internal Medicine. Arch Intern Med. 2006;166(2):145. doi:10.1001/archinte.166.2.145
Create a personal account or sign in to: